新加坡首次批准Junshi生物科学药物Tripalimab治疗高级鼻喉癌。 Junshi Biosciences' drug toripalimab is first approved in Singapore to treat advanced nasopharyngeal cancer.

新加坡已批准Junshi生物科学的免疫-肿瘤药物Tripalimab, 用于在手术或放射治疗无法选择时治疗复发性或转移性鼻腔癌。 Junshi Biosciences' immuno-oncology drug, toripalimab, has been approved in Singapore for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) when surgery or radiotherapy is not an option. 这是新加坡首例由全国人大批准的此类治疗, 基于临床试验结果显示存活率有所改善。 It's the first such treatment approved for NPC in Singapore, based on clinical trial results showing improved survival rates. 托里帕利马布现在在超过35个国家获得授权。 Toripalimab is now authorized in over 35 countries. Junshi生物科学旨在扩大全球范围获得创新性癌症治疗的机会。 Junshi Biosciences aims to expand access to innovative cancer treatments globally.